Amgen beats expectations as 2nd-qtr revenues rise 13% and EPS grows 34%
05:47 EDT 27 Jul 2012 | thePharmaLetter
The world's largest independent biotech company, USA-based Amgen (Nasdaq: AMGN), saw its shares move higher in after-hours trading when the firm announced better-than-expected financial results for the second quarter of 2012, with total revenues incr..
Original Article: Amgen beats expectations as 2nd-qtr revenues rise 13% and EPS grows 34%
More From BioPortfolio on "Amgen beats expectations as 2nd-qtr revenues rise 13% and EPS grows 34%"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
